| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/30/2002 | EP1175400A1 Renin inhibitors |
| 01/30/2002 | EP1175399A1 Inhibitors of c-jun n-terminal kinases (jnk) |
| 01/30/2002 | EP1175398A1 Indoline derivatives as progesterone antagonists |
| 01/30/2002 | EP1175397A1 3,3-substituted indoline derivatives |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175205A2 Inhibitors of crystallization in a solid dispersion |
| 01/30/2002 | EP1045897B1 Enzyme catalyzed therapeutic agents |
| 01/30/2002 | EP1021442B1 8-azabicyclo 3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors |
| 01/30/2002 | EP1019395B1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 01/30/2002 | EP1001765A4 Internal two photon excitation device for delivery of pdt to diffuse abnormal cells |
| 01/30/2002 | EP0937044B1 Cftr channel activator compounds and pharmaceutical compositions containing same |
| 01/30/2002 | EP0934267B1 Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
| 01/30/2002 | EP0900225B1 Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| 01/30/2002 | EP0891187B1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents |
| 01/30/2002 | EP0888373A4 Smooth muscle cell lim protein |
| 01/30/2002 | EP0832198A4 Oxygen activatable formulations for disinfection or sterilization |
| 01/30/2002 | EP0819136B1 Mdp derivatives and conjugates having haematopoietic function stimulating activity, and compositions containing same |
| 01/30/2002 | EP0564502B1 Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| 01/30/2002 | CN1333820A Recombinant methods and materials for producing epothilone and eopthilone derivatives |
| 01/30/2002 | CN1333818A Bioengineered tissue constructs and method for producing and using them |
| 01/30/2002 | CN1333784A Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333781A Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333780A Benzylglycosylmmides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333779A Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333778A Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333774A Substituted benzofuranodindoles and indenoindoles as novel potassium channel openers |
| 01/30/2002 | CN1333770A Novel dicyclic compound |
| 01/30/2002 | CN1333766A Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors |
| 01/30/2002 | CN1333762A Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives |
| 01/30/2002 | CN1333758A Substituted bicyclic derivatives useful as anticancer agents |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1333756A Crystalline bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino] pyrimidin-5-yl](3R,5S-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| 01/30/2002 | CN1333755A Benzimidazole compounds that are vitronectin receptor antagonists |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333753A Quinolinecarboxamides as antiviral agents |
| 01/30/2002 | CN1333698A Combination chemotherapy |
| 01/30/2002 | CN1333688A Method and compositions for improving allogeneic hematopoietic cell transplantation |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333680A Oral formulation for gastrointestinal drug delivery |
| 01/30/2002 | CN1333339A Polytype gene of MXA protein and application thereof |
| 01/30/2002 | CN1333039A Poria repercussion powder medicine |
| 01/30/2002 | CN1078473C Medicine for regulating menstruation and arresting bleedingand producing process therefor |
| 01/29/2002 | US6342765 Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| 01/29/2002 | US6342602 Bind specifically or selectively to rar-alpha receptors |
| 01/29/2002 | US6342596 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342533 Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders |
| 01/29/2002 | US6342531 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342511 Racemic, enantiomorphs and diasteriomorphs |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342509 Antiasthmatics, antihistamines or bronchodialators |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342502 Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases |
| 01/29/2002 | US6342498 Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists |
| 01/29/2002 | US6342496 Bupropion metabolites and methods of use |
| 01/29/2002 | US6342489 Treatment of iron deficiency with ferric salt of bis hemisuccinylursodeoxycholic acid |
| 01/29/2002 | US6342487 Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid |
| 01/29/2002 | US6342476 Treating multiple sclerosis by administering a copolymer reacted with hydrobromic acid |
| 01/29/2002 | US6342374 Human collagenase inhibitor, recombinant vector system for using same and recombinant-DNA method for the manufacture of same |
| 01/29/2002 | US6342254 Anti-proliferative preparations |
| 01/29/2002 | US6342234 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| 01/29/2002 | US6342221 Antibody conjugate compositions for selectively inhibiting VEGF |
| 01/29/2002 | US6342219 As anti-angiogenic and in tumor therapy |
| 01/29/2002 | CA2216789C Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
| 01/29/2002 | CA2145296C Benzenealkanoic acids for cardiovascular diseases |
| 01/29/2002 | CA2079328C Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof |
| 01/29/2002 | CA2063127C Reduction in cutaneous atrophy |
| 01/29/2002 | CA2031368C Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline |
| 01/28/2002 | CA2354107A1 Topical compounds including glucosyl hydroxystilbenes and uses |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006481A1 Target of anticancer agent |
| 01/24/2002 | WO2002006462A2 Methylated nucleotide regulation of upa gene expression |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006340A2 Tetraspan protein and uses thereof |
| 01/24/2002 | WO2002006307A1 Reduced fk228 and use thereof |
| 01/24/2002 | WO2002006306A2 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 01/24/2002 | WO2002006293A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | WO2002006286A2 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006282A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 01/24/2002 | WO2002006278A1 Oxazolidinone derivatives as antimicrobials |
| 01/24/2002 | WO2002006276A1 Beta3 adrenergic agonists |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006264A1 Lipid-rich plaque inhibitors |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006249A1 Method for producing 1-substituted-1,2,3-triazole derivative |
| 01/24/2002 | WO2002006248A2 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 01/24/2002 | WO2002006246A1 Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors |
| 01/24/2002 | WO2002006245A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006231A1 Serotonin reuptake inhibitors |
| 01/24/2002 | WO2002006227A1 Matrix metalloprotease inhibitors |